Assessing human cardiac allograft rejection using MRI with Gd-DOTA

Journal of Computer Assisted Tomography
E MousseauxJ C Gaux

Abstract

To explore the potential role of MRI in detecting cardiac allograft rejection in transplant recipients using gadolinium tetraazacyclododecane tetraacetic acid (Gd-DOTA) for contrast enhancement, we examined 7 normal healthy volunteers and 39 patients separated into three groups according to histological findings. Quantitative myocardial enhancement (ME), expressed as the ratio of maximum signal intensity after intravenous Gd-DOTA injection to signal intensity before intravenous injection of Gd-DOTA, was significantly lower for patients without histological rejection (n = 14; regional ME = 83 +/- 41%; mean ME = 53 +/- 24%) when compared with patients with grade 1 histological rejection (n = 18; regional ME = 122 +/- 20%, p = 0.02; mean ME = 70 +/- 14%, p < 0.05) and with patients with grade 2 or 3 rejection (n = 7; regional ME = 135 +/- 44%, p = 0.02; mean ME = 81 +/- 27%, p < 0.05). Myocardial enhancement was not significantly different in patients with grade 1 histological rejection compared with patients with grade 2 or 3 rejection. Because predominant focal areas of ME were observed in all patients, regional ME seemed a better measurement than mean ME to distinguish focal histological changes when the rejection process is be...Continue Reading

Citations

Mar 17, 2009·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·Craig R ButlerIan Paterson
Jan 9, 2007·The International Journal of Cardiovascular Imaging·Andrew L RivardNorbert Wilke
Dec 6, 2002·Biomedizinische Technik. Biomedical Engineering·J AlbersC F Vahl
Mar 31, 2015·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Jon A Kobashigawa
Aug 16, 2016·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Adam K McDiarmidHeather J Ross
Mar 21, 2017·Expert Review of Cardiovascular Therapy·Sophie I MavrogeniGenovefa Kolovou
Mar 18, 2017·Current Opinion in Cardiology·Maria G Crespo-LeiroDavid Couto-Mallon
Nov 5, 1999·Journal of Magnetic Resonance Imaging : JMRI·H Frank, S Globits
Sep 10, 2003·Transplantation Proceedings·L AlmenarM Palencia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.